Long-term follow-up of bilateral hip and knee arthroplasty secondary to ochronotic arthropathy

Ilyas, Imran; Kashif, Syed; Algashiri, Majed F.; Rabbani, Samar A.; Aldakhil, Sahar S.; Al-Mohrej, Omar A.

doi:10.1016/j.artd.2020.01.012

Cited by 9 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, assessments of the invasiveness of CTV and the accuracy of the Well score should be considered in future studies, based on which routine US should be performed as a less invasive test for screening patients with high Well scores. Likewise, the patients treated with THA for reasons other than osteoarthrits, such as the neck or femoral fractures 33 and ochronotic arthropathy, 34 should be included in future studies to examine the incidence of silent DVT and the effect of different anticoagulants.…”

Section: Discussionmentioning

confidence: 99%

Incidence of silent venous thromboembolism after total hip arthroplasty: A comparison of rivaroxaban and enoxaparin

Rahman

Habsa

Al-Mohrej

et al. 2020

J Orthop Surg (Hong Kong)

Self Cite

View full text Add to dashboard Cite

Propose: Total hip arthroplasty (THA) is associated with a significant risk of venous thromboembolism (VTE). Different thromboprophylaxis strategies have been used to prevent VTE. The primary aim of this study was to report the incidence of VTE and compare the efficacy and safety of rivaroxaban to enoxaparin. The secondary outcome was to report the incidence of silent deep venous thrombosis (DVT) using computed tomography venography. Methods: One hundred sixty patients who underwent THA were enrolled in a prospective study. Patients were randomized into two groups as follows: those who received rivaroxaban 10 mg oral daily (group RXE) and those who received enoxaparin 40 IU/day subcutaneously for 14 days (group ENO). Results: Both groups were matched for age, sex, comorbidities, special habits and preoperative laboratory investigations. The overall incidence of DVT was 5% ( n = 8), which included four patients clinically diagnosed as having DVT and four with silent DVT. All the DVT cases occurred in veins below the knee and in the group RXE; none of the cases occurred in group ENO ( p = 0.04). The incidence of DVT was significantly higher in patients with high body mass indexes ( p < 0.001), older age ( p = 0.024) and medical comorbidities ( p = 0.14). No mortality, pulmonary embolism, stroke, wound infection or major bleeding occurred in either group. Conclusions: Among the patients who underwent hip arthroplasty, rivaroxaban prophylaxis was found to be associated with lower efficacy and similar safety outcomes as compared with enoxaparin anticoagulants.

show abstract

Section: Discussionmentioning

confidence: 99%

Incidence of silent venous thromboembolism after total hip arthroplasty: A comparison of rivaroxaban and enoxaparin

Rahman

Habsa

Al-Mohrej

et al. 2020

J Orthop Surg (Hong Kong)

Self Cite

View full text Add to dashboard Cite

show abstract

“…(Figure 2.) In the late phase of joint degeneration, joint replacement surgery may be performed, and it is considered to be a safe and valid treatment option [34][35][36][37] . (Figure 3.)…”

Section: Treatmentmentioning

confidence: 99%

Arthropathia ochronotica

Matoković¹,

Plečko²,

Crnogaća³

et al. 2020

Rad Hrvatske akademije znanosti i umjetnosti

View full text Add to dashboard Cite

Alkaptonuria (AKU) is a rare autosomal recessive metabolic disease caused by a disorder of phenylalanine and tyrosine metabolism, resulting in accumulation and deposition of homogentisic acid (HGA) in the body. This deposition further causes progressive functional disorders in different organ systems, with the locomotor system being the most affected one. A specific triad of symptoms occurs in patients suffering from AKU: 1. at birth, a change of urine color is present when urine is exposed to air, 2. occurrence of dark pigmentations in connective tissues becomes visible over time, 3. complications of the locomotor, urogenital and cardiovascular systems present gradually. Arthropathia ochronotica occurs in patients suffering from AKU due to precipitation and deposition of HGA in the joint tissue (cartilage, tendons, ligaments, menisci, etc.). The accumulation can be seen as small foci of blue-black pigmentations. HGA deposits in collagen fibers, causing tendons and ligaments thickening. This causes them to be less resistant to mechanical forces, resulting in frequent ruptures caused by minimal trauma. Also, the deposition facilitates cartilage degeneration, often requiring an operative treatment. The knees are the most commonly affected joints, while changes can be seen in the spine and other large joints. As there is no specific treatment, alleviation of symptoms is the only treatment option. It has the goal of increasing individual functionality and quality of life. As an option for end-stage treatment, joint replacement surgery proved to be effective. In the future, an enzyme replacement therapy or gene therapy may be developed to treat AKU successfully.

show abstract

Principles of bone and tissue banking in Saudi Arabia: 10-year experience report

et al. 2020

View full text Add to dashboard Cite

Long-term follow-up of bilateral hip and knee arthroplasty secondary to ochronotic arthropathy

Cited by 9 publications

References 31 publications

Incidence of silent venous thromboembolism after total hip arthroplasty: A comparison of rivaroxaban and enoxaparin

Incidence of silent venous thromboembolism after total hip arthroplasty: A comparison of rivaroxaban and enoxaparin

Arthropathia ochronotica

Principles of bone and tissue banking in Saudi Arabia: 10-year experience report

Contact Info

Product

Resources

About